DPE1, a novel allelic of BT1, is critical for maize endosperm development and carbohydrate metabolism
- PMID: 40812577
- DOI: 10.1016/j.plantsci.2025.112720
DPE1, a novel allelic of BT1, is critical for maize endosperm development and carbohydrate metabolism
Abstract
Maize (Zea mays) endosperm is the primary tissue for storing nutrients, such as starch, that provide the developing embryo with energy. Endosperm mutants are useful for clarifying carbohydrate synthesis and metabolism as well as the molecular mechanism underlying endosperm development in maize. In this study, we identified a novel maize mutant exhibiting abnormal endosperm development. This mutant, which was named dysplastic endosperm1 (dpe1), contained a shrunken, collapsed, and opaque endosperm. Using a map-based cloning strategy, DPE1 was identified as Zm00001d015746. Moreover, an allelism test confirmed that DPE1 is allelic to the previously reported gene ZmBT1. The dpe1 mutant phenotype was revealed to be due to a single-nucleotide substitution that results in the substitution of a single amino acid. DPE1, which was highly expressed in kernels, was predicted to encode an ADP-glucose transporter localized in the chloroplast. Analyses of phylogenetic relationships and functional evolution suggested that this ADP-glucose transporter may have distinct functions in monocotyledons and dicotyledons. Transcriptome analyses and quantitative detection of small-molecule carbohydrate compounds indicated that differentially expressed genes and differentially abundant metabolites were significantly associated with carbohydrate metabolism-related pathways, implying that loss-of-function mutations to DPE1 lead to inhibited carbohydrate synthesis and transport. Thus, our study provides insights into the molecular basis of maize kernel endosperm development as well as genetic resources for the molecular breeding of maize.
Keywords: ADP-glucose transporter; Carbohydrate metabolism; DPE1; Endosperm; Zea mays.
Copyright © 2025. Published by Elsevier B.V.
Conflict of interest statement
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Similar articles
-
Prescription of Controlled Substances: Benefits and Risks.2025 Jul 6. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. 2025 Jul 6. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. PMID: 30726003 Free Books & Documents.
-
Systemic treatments for metastatic cutaneous melanoma.Cochrane Database Syst Rev. 2018 Feb 6;2(2):CD011123. doi: 10.1002/14651858.CD011123.pub2. Cochrane Database Syst Rev. 2018. PMID: 29405038 Free PMC article.
-
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.Cochrane Database Syst Rev. 2017 Dec 22;12(12):CD011535. doi: 10.1002/14651858.CD011535.pub2. Cochrane Database Syst Rev. 2017. Update in: Cochrane Database Syst Rev. 2020 Jan 9;1:CD011535. doi: 10.1002/14651858.CD011535.pub3. PMID: 29271481 Free PMC article. Updated.
-
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.Cochrane Database Syst Rev. 2021 Apr 19;4(4):CD011535. doi: 10.1002/14651858.CD011535.pub4. Cochrane Database Syst Rev. 2021. Update in: Cochrane Database Syst Rev. 2022 May 23;5:CD011535. doi: 10.1002/14651858.CD011535.pub5. PMID: 33871055 Free PMC article. Updated.
-
Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19.Cochrane Database Syst Rev. 2022 May 20;5(5):CD013665. doi: 10.1002/14651858.CD013665.pub3. Cochrane Database Syst Rev. 2022. PMID: 35593186 Free PMC article.
LinkOut - more resources
Full Text Sources